Stock BIOVERATIV INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Bioverativ Inc Stock

Equities

US09075E1001

Biotechnology & Medical Research

Chart Bioverativ Inc

Dynamic Chart

Latest news about Bioverativ Inc

Sanofi : sees new acquisitions and drugs reviving growth RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid RE
Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract RE
Ablynx : Sanofi's return to profit growth this year slower than hoped RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom RE
Stocks hit record as senators reach deal to end shutdown RE
Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion RE
Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion RE
Bioverativ : Sanofi shares fall on $11.6 billion Bioverativ takeover RE
More news

Press releases Bioverativ Inc

Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease BU
Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A BU
Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance BU
WeissLaw LLP : Investigates Bioverativ Inc. Acquisition PR
Bragar Eagel & Squire, P.C. : is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm BU
More press releases

News in other languages on Bioverativ Inc

Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
Sanofi finalise l'acquisition de Bioverativ
Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
Sanofi : franchit une étape dans son offre sur Bioverativ​
Sanofi: Amélioration attendue en 2018 plus lente que prévu
More news

Managers and Directors - Bioverativ Inc

Managers TitleAgeSince
William Sibold PSD
 President - 18-03-07
Joann Nestor SEC
 Corporate Secretary - -
Timothy J.R. Harris PRN
 Corporate Officer/Principal - -
Members of the board TitleAgeSince
William Sibold PSD
 President - 18-03-07
Philippe Sauvage BRD
 Director/Board Member - 18-03-07
More insiders

Company Profile

More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. Stock